Rapamycin: One Drug, Many Effects

Overview

Journal Cell Metab

Publisher Cell Press

Specialties Cell Biology
Endocrinology

Date 2014 Feb 11

PMID 24508508

Citations 558

Authors

Jing Li

Sang Gyun Kim

John Blenis

Affiliations

Soon will be listed here.

Abstract

The mammalian target of rapamycin (mTOR) signaling pathway is a master regulator of cell growth and metabolism. Deregulation of the mTOR pathway has been implicated in a number of human diseases such as cancer, diabetes, obesity, neurological diseases, and genetic disorders. Rapamycin, a specific inhibitor of mTOR, has been shown to be useful in the treatment of certain diseases. Here we discuss its mechanism of action and highlight recent findings regarding the effects and limitations of rapamycin monotherapy and the potential utility of combination therapy with rapamycin.

Citing Articles

Morpholine-Substituted Tetrahydroquinoline Derivatives as Potential mTOR Inhibitors: Synthesis, Computational Insights, and Cellular Analysis.

Dey R, Shaw S, Yadav R, Patel B, Bhatt H, Natesan G Cancers (Basel). 2025; 17(5).

PMID: 40075606 PMC: 11898650. DOI: 10.3390/cancers17050759.

Enhanced epigenetic modulation via mRNA-encapsulated lipid nanoparticles enables targeted anti-inflammatory control.

Mokhtari T, Taheri M, Akhlaghi S, Aryannejad A, Xiang Y, Mahajan V bioRxiv. 2025; .

PMID: 40060445 PMC: 11888353. DOI: 10.1101/2025.02.24.639996.

Advanced RPL19-TRAP-seq method reveals mechanism of action of bioactive compounds.

Zhu D, Hu J, Tan R, Lin X, Wang R, Lu J Nat Prod Bioprospect. 2025; 15(1):16.

PMID: 40042546 PMC: 11882491. DOI: 10.1007/s13659-025-00500-3.

Protein Arginine Methyltransferase 1: A Multi-Purpose Player in the Development of Cancer and Metabolic Disease.

de Korte D, Hoekstra M Biomolecules. 2025; 15(2).

PMID: 40001488 PMC: 11852820. DOI: 10.3390/biom15020185.

Dual Translational Control in Cardiomyocytes by Heterogeneous mTORC1 and Hypertrophic ERK Activation.

Uchida K, Scarborough E, Prosser B bioRxiv. 2025; .

PMID: 39990478 PMC: 11844361. DOI: 10.1101/2025.02.10.635974.

References

Mendoza M, Er E, Blenis J . The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation. Trends Biochem Sci. 2011; 36(6):320-8. PMC: 3112285. DOI: 10.1016/j.tibs.2011.03.006. View

Menon S, Manning B . Common corruption of the mTOR signaling network in human tumors. Oncogene. 2009; 27 Suppl 2:S43-51. PMC: 3752670. DOI: 10.1038/onc.2009.352. View

Sato A, Kasai S, Kobayashi T, Takamatsu Y, Hino O, Ikeda K . Rapamycin reverses impaired social interaction in mouse models of tuberous sclerosis complex. Nat Commun. 2012; 3:1292. PMC: 3535343. DOI: 10.1038/ncomms2295. View

McCormack F, Inoue Y, Moss J, Singer L, Strange C, Nakata K . Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N Engl J Med. 2011; 364(17):1595-606. PMC: 3118601. DOI: 10.1056/NEJMoa1100391. View

Wander S, Hennessy B, Slingerland J . Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy. J Clin Invest. 2011; 121(4):1231-41. PMC: 3069769. DOI: 10.1172/JCI44145. View

Kuo C, Chung J, Fiorentino D, Flanagan W, Blenis J, Crabtree G . Rapamycin selectively inhibits interleukin-2 activation of p70 S6 kinase. Nature. 1992; 358(6381):70-3. DOI: 10.1038/358070a0. View

Loewith R, Hall M . Target of rapamycin (TOR) in nutrient signaling and growth control. Genetics. 2011; 189(4):1177-201. PMC: 3241408. DOI: 10.1534/genetics.111.133363. View

Thoreen C, Sabatini D . Rapamycin inhibits mTORC1, but not completely. Autophagy. 2009; 5(5):725-6. DOI: 10.4161/auto.5.5.8504. View

Chung J, Kuo C, Crabtree G, Blenis J . Rapamycin-FKBP specifically blocks growth-dependent activation of and signaling by the 70 kd S6 protein kinases. Cell. 1992; 69(7):1227-36. DOI: 10.1016/0092-8674(92)90643-q. View

10.

Fang Y, Westbrook R, Hill C, Boparai R, Arum O, Spong A . Duration of rapamycin treatment has differential effects on metabolism in mice. Cell Metab. 2013; 17(3):456-62. PMC: 3658445. DOI: 10.1016/j.cmet.2013.02.008. View

11.

Ma X, Blenis J . Molecular mechanisms of mTOR-mediated translational control. Nat Rev Mol Cell Biol. 2009; 10(5):307-18. DOI: 10.1038/nrm2672. View

12.

Krebs M, Brunmair B, Brehm A, Artwohl M, Szendroedi J, Nowotny P . The Mammalian target of rapamycin pathway regulates nutrient-sensitive glucose uptake in man. Diabetes. 2007; 56(6):1600-7. DOI: 10.2337/db06-1016. View

13.

Tremblay F, Marette A . Amino acid and insulin signaling via the mTOR/p70 S6 kinase pathway. A negative feedback mechanism leading to insulin resistance in skeletal muscle cells. J Biol Chem. 2001; 276(41):38052-60. DOI: 10.1074/jbc.M106703200. View

14.

Houde V, Brule S, Festuccia W, Blanchard P, Bellmann K, Deshaies Y . Chronic rapamycin treatment causes glucose intolerance and hyperlipidemia by upregulating hepatic gluconeogenesis and impairing lipid deposition in adipose tissue. Diabetes. 2010; 59(6):1338-48. PMC: 2874694. DOI: 10.2337/db09-1324. View

15.

Laplante M, Sabatini D . mTOR signaling in growth control and disease. Cell. 2012; 149(2):274-93. PMC: 3331679. DOI: 10.1016/j.cell.2012.03.017. View

16.

Cornu M, Albert V, Hall M . mTOR in aging, metabolism, and cancer. Curr Opin Genet Dev. 2013; 23(1):53-62. DOI: 10.1016/j.gde.2012.12.005. View

17.

Yu J, Henske E . mTOR activation, lymphangiogenesis, and estrogen-mediated cell survival: the "perfect storm" of pro-metastatic factors in LAM pathogenesis. Lymphat Res Biol. 2010; 8(1):43-9. PMC: 2883473. DOI: 10.1089/lrb.2009.0020. View

18.

Johnson S, Yanos M, Kayser E, Quintana A, Sangesland M, Castanza A . mTOR inhibition alleviates mitochondrial disease in a mouse model of Leigh syndrome. Science. 2013; 342(6165):1524-8. PMC: 4055856. DOI: 10.1126/science.1244360. View

19.

Bell A, Grunder L, Sorisky A . Rapamycin inhibits human adipocyte differentiation in primary culture. Obes Res. 2000; 8(3):249-54. DOI: 10.1038/oby.2000.29. View

20.

Price D, Grove J, Calvo V, Avruch J, Bierer B . Rapamycin-induced inhibition of the 70-kilodalton S6 protein kinase. Science. 1992; 257(5072):973-7. DOI: 10.1126/science.1380182. View